TAO Synergies (TAOX) Common Equity (2019 - 2026)
TAO Synergies' (TAOX) quarterly Common Equity came in at $12.7 million in Q2 2026, down 26.09% on a YoY basis from $17.2 million in Q2 2025, and down 45.18% quarter-over-quarter from $23.3 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Common Equity (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Common Equity for 8 consecutive years, with $12.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Common Equity fell 26.09% year-over-year to $12.7 million; the trailing twelve-month figure through Jun 2026 stood at $12.7 million (down 26.09% YoY), and the FY2025 full-year result was $21.1 million, up 259.01% from the prior year.
- Common Equity eased to $12.7 million in Q2 2026 per TAOX's latest filing, from $23.3 million in the prior quarter.
- Across five years, Common Equity topped out at $32.7 million in Q4 2022 and bottomed at $5.2 million in Q1 2025.
- Historically, Common Equity has averaged $21.2 million across 5 years, with a median of $22.7 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Common Equity plunged 76.56% in 2025, then soared 349.98% in 2026.
- Over 5 years, Common Equity stood at $32.7 million in 2022, then retreated by 25.53% to $24.3 million in 2023, then tumbled by 75.92% to $5.9 million in 2024, then jumped by 259.01% to $21.1 million in 2025, then plunged by 39.44% to $12.7 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $12.7 million, $23.3 million, and $21.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.98 Bn | 196.99 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 181.24 Bn | 178.06 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 132.38 Bn | 124.53 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.97 Bn | 74.97 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 54.80 Bn | 49.67 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 34.09 Bn | 30.78 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.34 Bn | 30.05 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn | 4.92 Bn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | 12.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.75 Mn |
| Mar 31, 2026 | 23.26 Mn |
| Dec 31, 2025 | 21.05 Mn |
| Sep 30, 2025 | 16.07 Mn |
| Jun 30, 2025 | 17.25 Mn |
| Mar 31, 2025 | 5.17 Mn |
| Dec 31, 2024 | 5.86 Mn |
| Sep 30, 2024 | 12.80 Mn |
| Jun 30, 2024 | 18.80 Mn |
| Mar 31, 2024 | 22.05 Mn |
| Dec 31, 2023 | 24.35 Mn |
| Sep 30, 2023 | 26.74 Mn |
| Jun 30, 2023 | 24.83 Mn |
| Mar 31, 2023 | 31.46 Mn |
| Dec 31, 2022 | 32.69 Mn |
| Sep 30, 2022 | 26.67 Mn |
| Jun 30, 2022 | 28.95 Mn |
| Mar 31, 2022 | 31.68 Mn |
| Dec 31, 2021 | 33.53 Mn |
| Sep 30, 2021 | 31.35 Mn |